Survodutide vs Tirzepatide
Two different second hormones bolted onto GLP-1: tirzepatide adds GIP and is approved, survodutide adds glucagon and is investigational despite Phase 3 results.
Survodutide
A GLP-1/glucagon dual agonist in Phase 3 for both obesity and MASH; genuine placebo-controlled efficacy data in both indications, but no approval anywhere yet.
Full Survodutide evidence reviewTirzepatide
Zepbound / Mounjaro
Up to ~21% mean weight loss in SURMOUNT-1 — the most effective FDA-approved weight-management drug.
Full Tirzepatide evidence reviewSide by side
| Survodutide | Tirzepatide | |
|---|---|---|
| Marketed for | Weight loss, MASH | Weight loss, type-2 diabetes |
| Evidence grade | Clinical data | FDA-approved |
| Family | GLP-1 / incretin | GLP-1 / incretin |
| Regulatory status | Investigational | FDA-approved |
| How it's obtained | Research-only | Rx product |
| Key human source | Phase 2 obesity RCT, 2024 | SURMOUNT-1, NEJM 2022 |
marks a row where the two differ. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
Our verdict
Tirzepatide is both the more effective option and the only one of the two anyone can be prescribed — SURMOUNT-1 reported up to about 21% mean weight loss, the largest figure for any FDA-approved weight-management drug. Survodutide’s Phase 3 SYNCHRONIZE-1 reported about −16.6% over 76 weeks, a genuine result but a smaller one, and the two were never compared head to head. The mechanistic difference is the actual point of the comparison: survodutide’s glucagon-receptor arm is intended to raise energy expenditure and mobilise hepatic fat, which is why its liver data stand out — SYNCHRONIZE-MASLD reported 84.2% of participants cutting liver fat by at least 30%. That is a different target from tirzepatide’s GIP plus GLP-1 combination, so these are not simply stronger and weaker versions of one idea.
Survodutide fits if
You are following glucagon agonism, particularly for liver outcomes, and are tracking a drug not yet approved anywhere.
Tirzepatide fits if
You want the most effective approved weight-management medicine available today.